respisure one mycoplasma hyopneumoniae vaccine
zoetis australia pty ltd - mycoplasma hyopneumoniae - inactivated antigen; thiomersal - misc. vaccines or anti sera - mycoplasma hyopneumoniae - inactivated antigen vaccine-general active 31600.0 ru/2ml; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - mycoplasma hyopneumoniae | pneumonia | bacterial pneumonia | reduction of lung lesions | respiratory disease | swine enzootic pneumonia
respisure mycoplasma hyopneumoniae vaccine
zoetis australia pty ltd - m. hyopneumoniae - inactivated whole cell culture; thiomersal - misc. vaccines or anti sera - m. hyopneumoniae - inactivated whole cell culture vaccine-general active 6000.0 ru/do; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - mycoplasma hyopneumoniae | vaccine | equine rotavirus | reduction of lung lesions | respiratory disease | swine enzootic pneumonia
nalsen 5mg/ 2mg per 5ml syrup
iae pharmaceutical corporation; distributor: iae pharmaceuticals corporation - phenylephrine hydrochloride , brompheniramine maleate - syrup - 5mg/ 2mg per 5ml
m+pac mycoplasma hyopneumoniae inactivated vaccine for pigs
intervet australia pty limited - mycoplasma hyopneumoniae strain j; thiomersal - misc. vaccines or anti sera - mycoplasma hyopneumoniae strain j vaccine-general active 1.0 rp; thiomersal mercury other 0.01 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - mycoplasma hyopneumoniae | reduction of lung lesions | respiratory disease | swine enzootic pneumonia
imatinib teva pharma 400 milligram film coated tablet
teva pharma b.v. - imatinib mesilate - film coated tablet - 400 milligram - protein kinase inhibitors
imatinib teva pharma 100 milligram film coated tablet
teva pharma b.v. - imatinib mesilate - film coated tablet - 100 milligram - protein kinase inhibitors
imatinib teva pharma 100 mg film-coated tablets
teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - imatinib - film-coated tablet - imatinib 100 mg - antineoplastic agents
imatinib teva pharma 400 mg film-coated tablets
teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - imatinib - film-coated tablet - imatinib 400 mg - antineoplastic agents
ciprofloxacin tablet, film coated
denton pharma, inc. dba northwind pharmaceuticals - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin tablets are indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin tablets are indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin tablets are indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin tablet
bortezomib ever pharma bortezomib 3.5 mg/1.4 ml solution for injection vial
interpharma pty ltd - bortezomib, quantity: 3.5 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; mannitol - bortezomib ever pharma, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib ever pharma, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib ever pharma is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib ever pharma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.